Enrollment Advancing in Phase 2 Trial of NP-120 for Chronic Cough in IPF
Algernon Pharmaceuticals has announced that its Phase 2 trial of oral NP-120 (ifenprodil) in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) has reached 50% of its enrollment target. The proof-of-concept and open-label study (NCT04318704), currently underway at four sites in Australia and two in New…